4Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ.Ulcerative colitis. Lancet 2012; 380: 1606-1619 [PMID: 22914296DOI: 10.1016/S0140-6736(12)60150-0].
5Assadsangabi A, Lobo AJ. Diagnosing and managinginflammatory bowel disease. Practitioner 2013; 257: 13-8, 2[PMID: 24191430].
6Ye L, Cao Q, Cheng J. Review of inflammatory bowel diseasein China. ScientificWorldJournal 2013; 2013: 296470 [PMID:24348149 DOI: 10.1155/2013/296470].
7Danese S. New therapies for inflammatory bowel disease: fromthe bench to the bedside. Gut 2012; 61: 918-932 [PMID: 22115827DOI: 10.1136/gutjnl-2011-300904].
8Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T,Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van AsscheG. Second European evidence-based consensus on the diagnosisand management of ulcerative colitis part 2: current management.J Crohns Colitis 2012; 6: 991-1030 [PMID: 23040451 DOI:10.1016/j.crohns.2012.09.002].
10Yonekawa K, Harlan JM. Promises and limitations of targetingadhesion molecules for therapy. In: Ley K. Adhesion molecules:Function and inhibition. Basel (Switzerland): Birkh user VerlagAG, 2007: 289-330.
